Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | DTYMK | P23919 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29631631 | 1.00 | ELANE (0.55) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL31219308 | 0.84 | ELANE (0.47) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL13425915 | 0.84 | ELANE (0.47) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL30847426 | 0.83 | ELANE (0.55) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL18253173 | 0.83 | ELANE (0.46) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL30711710 | 0.83 | ELANE (0.55) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL2675518 | 0.83 | ELANE (0.55) | ELANEPOLBDTYMKDDB1CRBN | |
| SCHEMBL4569771 | 0.82 | L3MBTL1 (0.50) | ELANEPOLBDTYMKL3MBTL1 | |
| SCHEMBL30940044 | 0.82 | L3MBTL1 (0.47) | ELANEPOLBDTYMKL3MBTL1 | |
| SCHEMBL3705482 | 0.82 | L3MBTL1 (0.47) | ELANEPOLBDTYMKL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| CN-119546602-A | Pyrrolidone derivatives as inhibitors of nfkb-induced kinase | 詹森药业有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2021-01-28 | — | — | US | disclosed |
| EP-3133074-B1 | 7-AZAINDOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-12-09 | — | — | EP | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-101541783-A | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1345946-B1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6828327-B2 | For therapy of chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions, dementia, Alzheimer's disease, schizophrenia, manic depression, neurotraumatic, cognitive decline and ischemia-related diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1345946-A1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030078280-A1 | Macroheterocylic compounds useful as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2002046197-A1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078280-A1 | Macroheterocylic compounds useful as kinase inhibitors | PRKCH, MAP3K6, MAP3K2 | ELANE 4160/4885POLB 2584/4885DTYMK 188/4885 |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | ELANE 1971/4885POLB 1649/4885DTYMK 350/4885 |
| US-20250282785-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | ELANE 1771/4885POLB 518/4885DTYMK 197/4885 |
| US-20210024464-A1 | BINDING FUNCTION 3 (BF3) SITE COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | KLK3, SHBG, ACP3 | ELANE 1575/4885POLB 2166/4885DTYMK 2024/4885 |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ERBB2, EGFR, ERBB3 | ELANE 1971/4885POLB 1649/4885DTYMK 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.